Our work drew a comprehensive blueprint for the underlying mechanism through which SLC39A1 suppresses renal cell carcinoma progression and provided novel insight into the development of therapeutic targets and potential biomarkers for this disease. Here, SLC39A1 is linked to renal cell carcinoma.